Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains

Product Description

Launched in 2021.

Prequalified by the World Health Organization.

Manufacturing process is result of technology transfer from the WHO and Netherlands-based lntravacc.

Good safety with zero preservatives and antibiotics.

Read more on: http://www.sinovac.com/Vaccines/Poliomyelitis_Vaccine-en.html

Sinovac Biotech Ltd.

  • CN
  • 2018
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Clinical Research
Specifications
  • Selling Points
    Brand Name; Immune Health; International Approvals/Standards; Reputation
  • Supplied from
    China

Sinovac Biotech Ltd.

  • CN
  • 2018
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Clinical Research

More Products from Sinovac Biotech Ltd. (2)

  • Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive®

    Product Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive®

    • Hepatitis A Vaccine (Human Diploid Cell), Inactivated – Healive® Launched in 2002

    Hepatitis A & Hepatitis B Combined Vaccine – Bilive®
    Launched in 2005

    Healive® is:
    Prequalified by the World Health Organization.
    Provides susta...
  • Influenza Vaccine (Split Virion), lnactivated – Anflu®

    Product Influenza Vaccine (Split Virion), lnactivated – Anflu®

    Influenza Vaccine (Split Virion), lnactivated – Anflu®
    Pandemic Influenza Vaccine, lnactivated, Adjuvanted – Panflu®
    H1N1 Influenza A Vaccine (Split Virion), lnactivated – Panflu.1®
    Influenza Vaccine (Split Virion), lnactivated, Quadrivalent – TetrAnflu®

    Anflu®, preservative-free ...

Sinovac Biotech Ltd. resources (2)

  • News SINOVAC Named BogotáBio Exclusive Partner, Fueling New Vaccine Advances in Colombia

    Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced it has been named the exclusive strategic partner of BogotáBio, which will break ground as the first local human vaccine production facility to be established in Colombia’s capital city of Bogota.

  • Brochure SINOVAC Vaccines leaflets

    Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

    SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.